(078) Evaluating the Potential Utility of the SAVED Score in Predicting Venous Thromboembolism in a Veteran Cancer Population at VA San Diego

Poster Abstract:

Background:
Among those who are diagnosed with venous thromboembolism (VTE), approximately 20% of them have cancer. Patients with multiple myeloma who are treated with immunomodulatory drugs (IMIDs) have increased risk of VTE due to hemostatic pathways alteration; thus, promoting thrombogenesis. The National Comprehensive Cancer Network (NCCN) and International Myeloma Working Group (IMWG) have implemented VTE risk assessment models, such as the SAVED score, to identify the risk of VTE for MM individuals on IMID treatment. By validating this tool in the veteran cancer population at VA San Diego will allow clinicians to better identify a patient’s risk of developing VTE and prevent major complications including hospitalization and death.

Objective: To evaluate the risk of VTE using SAVED Score in veterans treated with IMiDs at the VA San Diego

Methodology: This is a retrospective chart review study that will evaluate the potential utility of the SAVED score in a veteran population with MM on IMiD therapy. High risk patients defined as a SAVED score tool rating of ≥ 2 points will be more likely to experience a venous thromboembolic event during the first four cycles of their initial cancer therapy compared to those who are not high risk. VTE will be classified as either a deep vein thrombosis (DVT) or pulmonary embolism (PE). Patients will be eligible for the study if they are at least 18 years of age or older and are newly diagnosed or relapsed/refractory MM and on IMiD therapy starting from October 1, 2016, to Oct 1, 2023. Patients’ history of surgery within 90 days; Asian race; history of VTE, age > 80, and dexamethasone dosing [standard (120-160 mg/cycle) or high (> 160 mg/cycle)] will be collected to tabulate their SAVED score. SAVED scores will be compared across groups. If patients were initiated on prophylactic anticoagulation in either group, this will be documented to assess the utility of the SAVED score in determining if prophylactic anticoagulation was appropriate. Anticoagulation therapies include enoxaparin, apixaban, rivaroxaban, fondaparinux, warfarin, and aspirin.

Results: N/A
Discussion/

Conclusions:
By evaluating the potential utility of the SAVED score in a veteran cancer population it will give clinicians an effective tool to stratify patients by VTE risk based on patient specific factors. Clinicians will be able to use SAVED score tool to decide if prophylactic anticoagulation is appropriate due to the risk of developing a life threatening VTE verse balancing the risks of serious bleeding.

References (must also be included in final poster): 1- Abu Zaanona MI, Mantha S. Cancer-Associated Thrombosis. [Updated 2023 Jul 17]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK562222/
2- Dima, Danai, et al. “External Validation of the Saved Score for Venous Thromboembolism Risk
Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs.” American
Society of Hematology, American Society of Hematology, 15 Nov. 2022,
ashpublications.org/blood/article/140/Supplement%201/11299/488790/External-Validation-of-the-
Saved-Score-for-Venous.
3- Author links open overlay panelShivani Kapur 1, et al. “Real World Validation of VTE Risk Models in
Newly Diagnosed Multiple Myeloma in a Community Setting.” Blood, Content Repository Only!, 24
Dec. 2021
4- Dima, Danai et al.British journal of hematology vol. 201,2 (2023): 280-284. doi:10.1111/bjh.18630
5- Covut, Fahrettin, and Kristen M. Sanfilippo. “Mitigating the Risk of Venous Thromboembolism in
Patients with Multiple Myeloma Receiving Immunomodulatory-Based Therapy.” American Society of
Hematology, American Society of Hematology, 9 Dec. 2022,
ashpublications.org/hematology/article/2022/1/363/493538/Mitigating-the-risk-of-venous-
thromboembolism-in.
6- NCCN, www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed 21 Nov. 2023.
7- Li, Ang et al. “Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-
Associated Thrombosis Among Patients With Multiple Myeloma.” Journal of the National
Comprehensive Cancer Network: JNCCN vol. 17,7 (2019): 840-847. doi:10.6004/jnccn.2018.7273
8- Dima, Danai et al. “External validation of the SAVED score for venous thromboembolism risk stratification in
patients with multiple myeloma receiving immunomodulatory drugs.” British journal of haematology vol. 201,2
(2023): 280-284. doi:10.1111/bjh.18630